About this conference
This oncology conference takes place in Dallas, Texas on Jan 15, 2027. Abstracts and papers are due by December 14, 2026. It is one of 16 upcoming oncology conferences in Texas; the next one after it starts on January 17. It is organized by iPHARMA Conferences.
Dedicated to exploring the impact of antibody-drug conjugates (ADCs) in cancer treatment, this event invites contributions from academicians, clinicians, and industry leaders. Participants can submit their abstract for presentations highlighting recent findings in ADC design, clinical advancements, and the implications for targeted therapy. The agenda will cover critical discussions on efficacy, patient selection, and overcoming obstacles in ADC utilization. Networking sessions are expected to promote valuable connections among attendees, facilitating future collaborations. This conference serves as an essential gathering to encourage discourse and advancements in ADCs as a treatment modality. Further details regarding registration and submission processes will be provided on the event’s website.
Topics
Details come from the organizer. Please check dates and fees on the conference website before you register or travel.